



**Biocon Limited**

20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/EA/2025-26/43

June 19, 2025

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code - 532523</b>	<b>Scrip Symbol - BIOCON</b>

Dear Sir/ Madam,

**Subject: Qualified Institutions Placement of equity shares of face value ₹ 5 each (“Equity Shares”) (such placement, the “Issue”) by Biocon Limited (the “Company”) under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and Sections 42, 23(1)(b) and 62(1)(c) of the Companies Act, 2013, as amended.**

In furtherance to our letter dated June 16, 2025, informing you about the opening of the issue and the floor price for the Issue, we wish to inform you that the Fund Raising Committee at its meeting held today i.e. Thursday, June 19, 2025, has, *inter alia*, passed the following resolutions:

- Approved the closure of the Issue today (i.e. Thursday, June 19, 2025) pursuant to the receipt of application forms and the funds in the escrow account from the eligible qualified institutional buyers in accordance with the terms of the Issue;
- Determined and approved, in accordance with the SEBI ICDR Regulations, the allocation of 136,363,635 Equity Shares at an Issue price of 330 per Equity Share, which is at a discount of ₹ 10.20 per Equity Share i.e. 3 % to the floor price of ₹ 340.20 per Equity Share, (including a premium of ₹ 325 per Equity Share) upon the closure of the Issue, according to the formula prescribed under Regulation 176(1) of the SEBI ICDR Regulations, as amended, for the Equity Shares to be allotted to the eligible qualified institutional buyers in the Issue; and
- Approved and finalized the confirmation of allocation note to be sent to eligible qualified institutional buyers, intimating them of the allocation of Equity Shares pursuant to the Issue.

The meeting of the Fund Raising Committee commenced at 7:30 PM and concluded at 7:45 PM.

The Issue was opened on Monday, June 16, 2025 and the same was intimated to you pursuant to our letter dated June 16, 2025.



We request you to kindly take this on records and treat the same as compliance under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations Disclosure Requirements) Regulations, 2015, as amended.

Copy of this intimation is being also made available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Siddharth Mittal**  
**Managing Director & CEO**  
**DIN: 03230757**